TRUE PARTNER (08657): Jialin Capital appointed as independent financial advisor, trading to resume on February 4th.
TRUE PARTNER (08657) announced that, in accordance with the terms of the bond subscription agreement, Mr. Jeronimus Mattheus Tielman and Ms. Bai Wanting will resign from their positions as independent non-executive directors upon the completion date of the convertible bonds. With the approval of the Independent Directors Committee, Jalin Capital has been appointed as the independent financial advisor in accordance with Rule 20.42 of the GEM Listing Rules to provide advice to the Independent Directors Committee and independent shareholders on the bond subscription agreement and the transactions contemplated thereunder, as well as the waiver of the whitewash.
TRUE PARTNER (08657) announced that Mr. Jeronimus Mattheus Tielman and Ms. Bai Wanting will resign from their positions as independent non-executive directors upon the completion date of the convertible bonds in accordance with the terms of the bond subscription agreement. With the approval of the Independent Directors Committee, Jalin Capital has been appointed as the independent financial advisor in accordance with Rule 20.42 of the GEM Listing Rules to provide advice to the Independent Directors Committee and independent shareholders on the bond subscription agreement and the transactions contemplated thereunder.
The company has applied to the Stock Exchange for the resumption of trading in its shares from 9:00 am on February 4, 2026.
Related Articles

HK Stock Market Move | ASCENTAGE-B(06855) increased by more than 3%. BTK degrader class 1 new drug APG-3288 tablets approved for clinical use.

CICC: Raised target price of EAST BUY (01797) to HK$30, Maintained "Outperform" rating.

China Securities Co., Ltd: This round of deposits moving towards standardized capital market tools, residents' wealth allocation moving towards diversified investment portfolios.
HK Stock Market Move | ASCENTAGE-B(06855) increased by more than 3%. BTK degrader class 1 new drug APG-3288 tablets approved for clinical use.

CICC: Raised target price of EAST BUY (01797) to HK$30, Maintained "Outperform" rating.

China Securities Co., Ltd: This round of deposits moving towards standardized capital market tools, residents' wealth allocation moving towards diversified investment portfolios.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


